Details for New Drug Application (NDA): 020886
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
NDA 020886 describes PANRETIN, which is a drug marketed by Concordia and is included in one NDA. It is available from one supplier. Additional details are available on the PANRETIN profile page.
The generic ingredient in PANRETIN is alitretinoin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alitretinoin profile page.
The generic ingredient in PANRETIN is alitretinoin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the alitretinoin profile page.
Summary for 020886
| Tradename: | PANRETIN |
| Applicant: | Concordia |
| Ingredient: | alitretinoin |
| Patents: | 0 |
| Formulation / Manufacturing: | see details |
Suppliers and Packaging for NDA: 020886
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PANRETIN | alitretinoin | GEL;TOPICAL | 020886 | NDA | Concordia Pharmaceuticals Inc. | 59212-601 | 59212-601-22 | 60 g in 1 TUBE (59212-601-22) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GEL;TOPICAL | Strength | EQ 0.1% BASE | ||||
| Approval Date: | Feb 2, 1999 | TE: | RLD: | Yes | |||||
Expired US Patents for NDA 020886
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Concordia | PANRETIN | alitretinoin | GEL;TOPICAL | 020886-001 | Feb 2, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| Concordia | PANRETIN | alitretinoin | GEL;TOPICAL | 020886-001 | Feb 2, 1999 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
